{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    8,
    9,
    10,
    14,
    15,
    16,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    39,
    40,
    41,
    42,
    43,
    44,
    47,
    48,
    49
  ],
  "modelUsed": "claude-opus-4-5",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Ontamalimab",
        "role": {
          "code": "Investigational Product",
          "codeSystem": "USDM",
          "decode": "Investigational Product"
        },
        "instanceType": "StudyIntervention",
        "description": "TAK-647, a fully human immunoglobulin G2 kappa antihuman MAdCAM-1 monoclonal antibody for treatment of NASH with fibrosis",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Ontamalimab prefilled syringe",
        "instanceType": "AdministrableProduct",
        "doseForm": {
          "code": "Solution",
          "codeSystem": "USDM",
          "decode": "Solution"
        },
        "strength": "75 mg/mL",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Takeda Pharmaceuticals"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Ontamalimab 75 mg Q4W",
        "instanceType": "Administration",
        "dose": "75 mg",
        "doseFrequency": "every 4 weeks (Q4W)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "24 weeks (last dose at Week 20)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "ontamalimab",
        "instanceType": "Substance",
        "description": "Fully human immunoglobulin G2 kappa antihuman MAdCAM-1 monoclonal antibody (previously known as PF-00547659 or SHP647)"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 1,
      "productCount": 1,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Ontamalimab",
        "role": "Investigational Product",
        "description": "TAK-647, a fully human immunoglobulin G2 kappa antihuman MAdCAM-1 monoclonal antibody for treatment of NASH with fibrosis"
      }
    ],
    "products": [
      {
        "name": "Ontamalimab prefilled syringe",
        "doseForm": "Solution for injection",
        "strength": "75 mg/mL",
        "manufacturer": "Takeda Pharmaceuticals"
      }
    ],
    "substances": [
      {
        "name": "ontamalimab",
        "description": "Fully human immunoglobulin G2 kappa antihuman MAdCAM-1 monoclonal antibody (previously known as PF-00547659 or SHP647)"
      }
    ],
    "administrations": [
      {
        "name": "Ontamalimab 75 mg Q4W",
        "dose": "75 mg",
        "frequency": "every 4 weeks (Q4W)",
        "route": "Subcutaneous",
        "duration": "24 weeks (last dose at Week 20)"
      }
    ],
    "devices": []
  }
}